These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 24526222)

  • 1. Hemolytic uremic syndrome.
    Mele C; Remuzzi G; Noris M
    Semin Immunopathol; 2014 Jul; 36(4):399-420. PubMed ID: 24526222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemolytic uremic syndrome in children.
    Talarico V; Aloe M; Monzani A; Miniero R; Bona G
    Minerva Pediatr; 2016 Dec; 68(6):441-455. PubMed ID: 27768015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of the Complement System in the Pathogenesis of Infectious Forms of Hemolytic Uremic Syndrome.
    Avdonin PP; Blinova MS; Generalova GA; Emirova KM; Avdonin PV
    Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38254639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical hemolytic uremic syndrome.
    Loirat C; Frémeaux-Bacchi V
    Orphanet J Rare Dis; 2011 Sep; 6():60. PubMed ID: 21902819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR; Johnson S
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M; Mescia F; Remuzzi G
    Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement disorders and hemolytic uremic syndrome.
    Joseph C; Gattineni J
    Curr Opin Pediatr; 2013 Apr; 25(2):209-15. PubMed ID: 23399570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HUS and the case for complement.
    Conway EM
    Blood; 2015 Oct; 126(18):2085-90. PubMed ID: 26396094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
    Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Unusual Case of Clostridium Difficile Colitis and Hemolytic Uremic Syndrome in a Teenager.
    Dasgupta K; Santos A; McCaul K
    S D Med; 2019 Jul; 72(7):294-297. PubMed ID: 31461583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome.
    Szilágyi A; Kiss N; Bereczki C; Tálosi G; Rácz K; Túri S; Györke Z; Simon E; Horváth E; Kelen K; Reusz GS; Szabó AJ; Tulassay T; Prohászka Z
    Nephrol Dial Transplant; 2013 Sep; 28(9):2237-45. PubMed ID: 23787556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.
    Alberti M; Valoti E; Piras R; Bresin E; Galbusera M; Tripodo C; Thaiss F; Remuzzi G; Noris M
    Am J Transplant; 2013 Aug; 13(8):2201-6. PubMed ID: 23731345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where are we with haemolytic uremic syndrome?
    Cavero T; Alonso M
    Med Clin (Barc); 2018 Oct; 151(8):329-335. PubMed ID: 29699703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HUS and atypical HUS.
    Jokiranta TS
    Blood; 2017 May; 129(21):2847-2856. PubMed ID: 28416508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
    Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
    Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atypical hemolytic uremic syndrome].
    Blasco Pelicano M; Rodríguez de Córdoba S; Campistol Plana JM
    Med Clin (Barc); 2015 Nov; 145(10):438-45. PubMed ID: 25433773
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.